SCHEMBL11933652

SCHEMBL11933652

CC(=O)c1cc(F)ccc1CN

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.43
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
MAOB P27338 5/20 0.42
MAOA P21397 2/20 0.39
MPO P05164 2/20 0.39
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DPP4 P27487 2/20 0.36
DPP7 Q9UHL4 2/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
IDO1 P14902 1/20 0.35
AGXT P21549 1/20 0.35
RIPK1 Q13546 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6755715 0.87 MAPK8 (0.44) KEAP1CES2CES1MPOSLC6A4
SCHEMBL17059405 0.85 MAOB (0.45) KEAP1CES2CES1MAOBMAOA
Hydrochloric Acid SCHEMBL4770593 0.85 MAPK8 (0.43) KEAP1CES2CES1MPOIDO1
SCHEMBL12304999 0.85 CES2 (0.45) KEAP1CES2CES1MAOBMAOA
SCHEMBL31658894 0.83 CES2 (0.44) KEAP1CES2CES1MAOBMAOA
Hydrochloric Acid SCHEMBL1654425 0.81 KEAP1 (0.56) KEAP1CES2CES1MPOALDH1A1
SCHEMBL2076694 0.81 SLC6A4 (0.44) KEAP1ALDH1A1SMN1; SMN2ALOX15SLC6A4
SCHEMBL14067847 0.81 KMT2A (0.40) KEAP1CES2CES1MAOBMPO
SCHEMBL1503262 0.81 GAA (0.43) KEAP1CES2CES1MPOALDH1A1
SCHEMBL8271785 0.80 LMNA (0.47) KEAP1CES2CES1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130296330-A1 MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS ELANCO ANIMAL HEALTH IRELAND LIMITED (US) 2013-11-07 US disclosed
US-8497270-B2 Macrocyclic integrase inhibitors ELANCO ANIMAL HEALTH IRELAND LIMITED (US) 2013-07-30 US disclosed
US-20120172367-A1 MACROCYCLIC INTEGRASE INHIBITORS ELANCO ANIMAL HEALTH IRELAND LIMITED (US) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296330-A1 MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS FIP1L1, PIM1, TYMP KEAP1 1976/4885CES2 2946/4885CES1 938/4885
US-20120172367-A1 MACROCYCLIC INTEGRASE INHIBITORS CCNI, CCNY, CDK7 KEAP1 3879/4885CES2 1264/4885CES1 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.